Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 15/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 2/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30187242 | 1.00 | KRAS (0.49) | KRASCRBNCNR1CNR2GBA1 | |
| SCHEMBL21458554 | 1.00 | KRAS (0.49) | KRASCRBNCNR1CNR2GBA1 | |
| SCHEMBL21458459 | 0.90 | KRAS (0.51) | KRASCRBNCNR1CNR2GBA1 | |
| SCHEMBL21458461 | 0.90 | KRAS (0.51) | KRASCRBNCNR1CNR2GBA1 | |
| SCHEMBL30085115 | 0.90 | KRAS (0.51) | KRASCRBNCNR1CNR2GBA1 | |
| SCHEMBL30187246 | 0.88 | KRAS (0.51) | KRASCRBNTLR9TLR7 | |
| SCHEMBL28983553 | 0.88 | KRAS (0.51) | KRASCRBNTLR9TLR7 | |
| SCHEMBL29939521 | 0.88 | KRAS (0.45) | KRAS | |
| SCHEMBL27003478 | 0.88 | KRAS (0.45) | KRAS | |
| SCHEMBL27140428 | 0.88 | KRAS (0.45) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| CN-115803030-A | Compounds and methods for KRAS-targeted degradation | 阿维纳斯企业公司 | 2023-03-14 | — | — | CN | disclosed |
| EP-4132655-A1 | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF KRAS | Arvinas Operations, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20220402907-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2022-12-22 | — | — | US | disclosed |
| US-20220370416-A1 | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF KRAS | YALE UNIVERSITY | 2022-11-24 | — | — | US | disclosed |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| EP-3774777-A2 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-112218859-A | Modulators of proteolysis and related methods of use | 阿尔维纳斯运营股份有限公司 | 2021-01-12 | — | — | CN | disclosed |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370416-A1 | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF KRAS | KRAS, MDM2, VHL | KRAS 1/4885CRBN 74/4885CNR1 4168/4885 |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | KRAS 242/4885CRBN 2/4885CNR1 4649/4885 |
| US-20220402907-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | KRAS 242/4885CRBN 2/4885CNR1 4649/4885 |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | CRBN, ADRM1, MDM2 | KRAS 289/4885CRBN 1/4885CNR1 3202/4885 |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | MDM2, CRBN, VHL | KRAS 242/4885CRBN 2/4885CNR1 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.